HWPC: The subsidiary's raw materials drug has received the approval notice for the listing application
HWPC announced that its wholly-owned subsidiary Hunan HWPC Pharmaceutical Co., Ltd. has received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Isoproterenol Hydrochloride and Levonorgestrel Tartrate. Isoproterenol Hydrochloride is used to treat cardiogenic or infectious shock, while Levonorgestrel Tartrate is used to control blood pressure in acute hypotensive states. This will enrich the company's product line and enhance its core competitiveness
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments